Palmetto
High payment rates for tests for rare disorders in regions covered by two Medicare Administrative Contractors could spark debate about genetic testing fraud.
Guardant Health Receives Medicare Coverage for MRD Liquid Biopsy in Stage II and III Colon Cancer
The Guardant Reveal assay will now be covered for this group of patients as long as testing is initiated within three months after surgery.
Adaptive Biotech's ClonoSeq Gets Expanded Medicare Coverage For B-Cell Lymphoma
The firm's assay is the first and only test to gain coverage for this patient population, for whom ctDNA MRD assessment can help personalize treatment.
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.
Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests
Tests like MDxHealth's SelectMDx, Bio-Techne's ExoDx Prostate, and various PSA scoring algorithms would be reimbursed if they pass a technical assessment.